STOCK TITAN

MyMD Pharmaceuticals Inc - MYMD STOCK NEWS

Welcome to our dedicated news page for MyMD Pharmaceuticals (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MyMD Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MyMD Pharmaceuticals's position in the market.

-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
MyMD Pharmaceuticals Inc

Nasdaq:MYMD

MYMD Rankings

MYMD Stock Data

5.18M
1.94M
1.06%
9.72%
5.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
West Deptford

About MYMD

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.